Saturday, 15 August 2020


BioSpectrum Asia's Top 20 Survey Special

29 May 2015 | News | By BioSpectrum Bureau

BioSpectrum Asia

It is time for the 2015 Annual Survey of the Asian Bioscience Industry and ranking of Top companies in Asia brought to you by BioSpectrum Asia! The Top 20 ranking has been an extensive annual exercise done by BioSpectrum team since the last eight years. The first survey was published in the June 2008 issue of BioSpectrum Asia edition.
This ranking are acknowledged and highly recognized by the industry and often used as a reference of growth and industry status. The rankings are done based on certain pre-defined parameters.

Here is an overview of what the content focus will be:

Part I:

  • Asia's Top 20: Profiling Asia's Top 20 listed companies by revenue across the region.
  • Market analysis: Industry survey of Asia Pacific bioscience market. Overall market size, growth and forecast by segment.
  • Country Analysis: Top companies by revenue in Australia, China, India, Malaysia, Singapore, South Korea, Taiwan. Also it will feature the market growth in the respective regions.



Part II:

  • Asia Fastest 50: Fastest growing 50 companies across Asia Pacific and the main reason which is instrumental in driving their growth.
  • M&A climate in Asia: The top deals in the region in the segment of pharma, biotech and medtech. Analyze, the nature of consolidation in the industry. 
  • Product Analysis: Asia's top selling products and also analyzes on why they have been positioned at the top.
  • Human Resource Analysis: Estimating & projecting the talent pool requirement


The survey activity has already started and this year we expect to cover the business activities of over 400 lifescience companies within the region. The previous survey results have shown that the overall industry growth by the end of 2013 was more than 12 percent which has propelled the industry size to $173 billion. The industry is expected to show the similar growth in 2014 (survey results awaited).

This is the most exhaustive and exclusive survey being conducted in Asia-Pacific and we urge you to use this platform to engage the bioscience community in Asia and make the best use of it to reach and remain in the minds of our readers. 


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls